Several GLP-1 pills are in development. Here's when you can expect this new wave of these popular weight-loss medications.

"However, in clinical trials, GLP-1 agonists reduce mortality by about 20%, and no single pharmaceutical treatment has ever demonstrated such profound mortality benefits," Gelfand, who has ...

A new oral weight loss medication, orforglipron, demonstrated meaningful weight loss results in phase 3 trials, potentially providing an easier alternative to Ozempic injections.

Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily 25-milligram semaglutide pill can trigger significant weight loss.

Makers of GLP-1 drugs, including Novo Nordisk, Eli Lilly and others, are close to releasing daily pills to help shed pounds as an alternative to weekly injections.

While Ozempic and other drugs like it have proven effective in helping people lose weight, many gain it back when the injections stop. A new drug targets weight loss differently, leading to a more ...

Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining ...

The market for illicit weight-loss drugs is booming in plain sight. And the U.S. Food and Drug Administration is starting to push back. In September, the FDA sent more than 50 warning letters to ...

A new Penn Nursing study suggests that the weight-loss drug tirzepatide may cause fewer side effects like nausea and vomiting than the drug semaglutide. This research, published in Science Advances, ...

Roche Holding AG will move an experimental obesity shot into late-stage trials next year in a bid to challenge leaders in the booming market for weight-loss medicines.

VIENNA, Sept 17 (Reuters) - Eli Lilly's (LLY.N), opens new tab bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and the company reaffirmed ...